Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Enveric Biosciences, Inc. (ENVB)

2.87   0.01 (0.35%) 01-27 15:59
Open: 2.78 Pre. Close: 2.86
High: 2.955 Low: 2.78
Volume: 28,172 Market Cap: 6(M)

Technical analysis

as of: 2023-01-27 4:44:10 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.59     One year: 4.2
Support: Support1: 2.14    Support2: 1.57
Resistance: Resistance1: 3.07    Resistance2: 3.59
Pivot: 2.77
Moving Average: MA(5): 2.84     MA(20): 2.67
MA(100): 3.42     MA(250): 8.51
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 69.4     %D(3): 71.8
RSI: RSI(14): 58.1
52-week: High: 34.34  Low: 0.18
Average Vol(K): 3-Month: 46 (K)  10-Days: 37 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ENVB ] has closed below upper band by 23.2%. Bollinger Bands are 74.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.96 - 2.97 2.97 - 2.98
Low: 2.75 - 2.76 2.76 - 2.78
Close: 2.85 - 2.87 2.87 - 2.89

Company Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Headline News

Sat, 28 Jan 2023
TDR's Top 5 Psychedelic Developments For The Week Of January 23 - The Dales Report

Thu, 12 Jan 2023
How Will the Market React to Enveric Biosciences Inc (ENVB) Stock Getting a Neutral Rating - InvestorsObserver

Wed, 21 Dec 2022
Enveric Biosciences to Present at the 6th Annual Neuroscience ... - Business Wire

Mon, 28 Nov 2022
Enveric Biosciences Announces Confidential Submission of ... - Business Wire

Mon, 24 Oct 2022
Enveric Biosciences Advances Lead Candidate for the Treatment of ... - Business Wire

Tue, 30 Aug 2022
7 Psychedelics Stocks to Buy for a Big Drug Boom - InvestorPlace

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 2 (M)
Shares Float 2 (M)
% Held by Insiders 9.6 (%)
% Held by Institutions 7.1 (%)
Shares Short 46 (K)
Shares Short P.Month 43 (K)

Stock Financials

EPS -1.67
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.98
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -33.4
Return on Equity (ttm) -131.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -12.7
Qtrly Earnings Growth 0
Operating Cash Flow -18 (M)
Levered Free Cash Flow -7 (M)

Stock Valuations

PE Ratio -1.73
PEG Ratio 0
Price to Book value 0.26
Price to Sales 0
Price to Cash Flow -0.34

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-11-24
Ex-Dividend Date 2008-04-22
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.